C-REGS2-A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke.

Study findings

The prospective comparative study associated Cerebrolysin with better 90-day functional outcomes in moderate ischemic stroke. It reported no difference in the assessed safety measures.

Population and setting

C-REGS2: 1,769 patients in the target population across 16 countries

Evidence type

Human comparative study

Preparation

See the original report; formulation details require verification.

Source language

eng

Title source

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

Study limitations

• Nonrandomized, open-label treatment; adjustment does not remove unmeasured confounding.
• This is observational effectiveness research, not a randomized trial.
• Full methods and risk of bias have not been independently assessed.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Source access and review scope

Indexed record and available abstract checked; full text not reviewed.

Recorded source-check date: 2026-10-07. This date does not imply a completed systematic review.

Open original source or index record ↗

DOI: 10.1177/17474930251375439

Citation and original source

Original source: Vosko MR, Sanak D, Do Y, Vatanagul JS, Roushdy T, Bornstein NM, Vester JC, Brainin M. C-REGS2-A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke. International journal of stroke : official journal of the International Stroke Society; 2025 Oct 2025.

Molekul research summary: https://molekul.io/research/cbl-update-40851188. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles